Applied Genetic Technologies Corporation (NASDAQ:AGTC) Getting Somewhat Critical Press Coverage, Accern Reports

News stories about Applied Genetic Technologies Corporation (NASDAQ:AGTC) have been trending somewhat negative this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Applied Genetic Technologies Corporation earned a news sentiment score of -0.16 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 100 out of 100, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the next several days.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

A number of equities research analysts recently commented on AGTC shares. Zacks Investment Research upgraded shares of Applied Genetic Technologies Corporation from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research report on Tuesday, April 11th. Stifel Nicolaus reduced their price objective on shares of Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, May 11th. ValuEngine downgraded shares of Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Cantor Fitzgerald set a $15.00 price objective on shares of Applied Genetic Technologies Corporation and gave the company a “hold” rating in a research report on Wednesday, May 10th. Finally, HC Wainwright set a $16.00 price objective on shares of Applied Genetic Technologies Corporation and gave the company a “buy” rating in a research report on Saturday, June 10th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $13.81.

Applied Genetic Technologies Corporation (NASDAQ AGTC) traded down 2.00% during midday trading on Tuesday, hitting $4.90. 187,802 shares of the stock were exchanged. The stock has a market cap of $88.57 million, a price-to-earnings ratio of 11.69 and a beta of 1.68. The firm’s 50-day moving average is $5.01 and its 200 day moving average is $6.20. Applied Genetic Technologies Corporation has a 52 week low of $4.50 and a 52 week high of $16.62.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.04. Applied Genetic Technologies Corporation had a net margin of 17.61% and a return on equity of 6.62%. The business had revenue of $8.39 million for the quarter, compared to analyst estimates of $10.39 million. During the same period in the prior year, the company earned $0.11 earnings per share. The firm’s revenue for the quarter was down 30.1% on a year-over-year basis. Equities research analysts expect that Applied Genetic Technologies Corporation will post $0.33 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Applied Genetic Technologies Corporation (NASDAQ:AGTC) Getting Somewhat Critical Press Coverage, Accern Reports” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/08/08/applied-genetic-technologies-corporation-nasdaqagtc-receives-daily-news-impact-rating-of-0-16-updated-updated-updated.html.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Insider Buying and Selling by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply